Kolmar BNH, an Original Design Manufacturing (ODM) company for health functional foods, has acquired certification for the additional functionality of HemoHIM, a renowned Korean health supplement, to strengthen its market position in the country.
A Kolmar BNH representative mentioned that the company has enhanced the competitiveness of HemoHIM through its own research and development (R&D) efforts. It has secured approval from the Ministry of Food and Drug Safety for the fatigue-improving function of the HemoHIM extract complex derived from angelica gigas and other components in 2023.
This new achievement was made 6 years after the launch of its HemoHIM Sustainable Technology Development Project. As a result, HemoHIM now came to the market as a dual-functional health product designed to boost immune function and reduce fatigue.
Distributed by Korea-based Atomy Co., Ltd, HemoHIM is now exported to over 20 countries generating Won 2 trillion (US$1.4 billion) in sales with exports exceeding US$200 million. HemoHIM is now Korea’s top-selling immune booster for more than a decade.
Kolmar BNH allocates over 2% of its annual sales to R&D, aiming to enhance product functionality and fortify competitive advantage of HemoHIM. HemoHIM G, targeting the global market, is one of the results of such dedication to R&D. Launched in Taiwan in June this year, HemoHIM G is a new product for export that has made meticulous adjustments to its raw materials and ingredient proportions to comply with international food regulations. Its key ingredients went through rigorous sourcing procedures and stringent quality control, while the taste and aroma profiles were tailored to suit the preferences of global consumers. Its safety has also been certified in the prestigious academic journal Toxicological Research accredited at the Science Citation Index Expanded (SCIE) level.